Last updated 4 days ago
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
620 patients around the world
Available in Spain, Mexico, United States
Eligible subjects will be randomized (1:1) to receive investigational product (ABP 206 or
nivolumab).
All subjects will be treated until disease progression, unacceptable toxicity, or subject
withdrawal of consent for a maximum of 24 months of treatment.
The total duration of study participation for each subject will be approximately 26
months.
Amgen
9Research sites
620Patients around the world
This study is for people with
Skin cancer
Melanoma
Requirements for the patient
To 99 Years
All Gender
Medical requirements
Sites
CIO - Centro de Inmuno-Oncología de Occidente
Recruiting
CIO - Centro de Inmuno-Oncología de Occidente
Recruiting
I CAN Oncology Center
Recruiting
I CAN Oncology Center
Recruiting
Centro De Estudio Y Prevención Del Cáncer - CEPREC - Oaxaca
Recruiting
Centro De Estudio Y Prevención Del Cáncer - CEPREC - Oaxaca
Recruiting
Oncare Cancer Center Viaducto CdMx
Recruiting
Oncare Cancer Center Viaducto CdMx
Recruiting
Clínica Integral Internacional de Oncología S. de R.L. de C.V.
Recruiting
Clínica Integral Internacional de Oncología S. de R.L. de C.V.
Recruiting
Centro de Atención e Investigación Cardiovascular del Potosí S.C.
Recruiting
Centro de Atención e Investigación Cardiovascular del Potosí S.C.
Recruiting
Althian Clinical Research
Recruiting
Althian Clinical Research
Recruiting
Centro Médico Zambrano Hellion
Recruiting
Centro Médico Zambrano Hellion
Recruiting
Clinical Research Institute S.C.
Recruiting
Clinical Research Institute S.C.
Recruiting
SponsorAmgen
Conditions
Melanoma
Requirements
To 99 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06054555
